Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Cited by (1,000)

Items 101–200 of 1,000

1. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
   Benjamin G. Barwick, Vikas Anand Gupta, Paula M. Vertino, Lawrence Boise · 2019 · Frontiers in Immunology
2. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
   Shaji Kunnathu Kumar, Natalie S. Callander, Kehinde Adekola, Larry Don Anderson, Muhamed Baljević, Rachid Baz, Erica Leigh Campagnaro, Jorge Julio Castillo, Caitlin L. Costello, Christopher Robert D'Angelo et al. · 2023 · Journal of the National Comprehensive Cancer Network
3. Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
   Richardson, Paul G., Weller, Edie, Jagannath, Sundar, Avigan, David E., Alsina, Melissa, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Ghobrial, Irene M., Doss, Deborah et al. · 2009 · Journal of Clinical Oncology
4. Association of response endpoints with survival outcomes in multiple myeloma
   Lonial, S, Anderson, K C · 2014 · Leukemia
5. Lenalidomide enhances anti-myeloma cellular immunity
   Luptakova, Katarina, Rosenblatt, Jacalyn, Glotzbecker, Brett, Mills, Heidi, Stroopinsky, Dina, Kufe, Turner, Vasir, Baldev, Arnason, Jon, Tzachanis, Dimitri, Zwicker, Jeffrey I. et al. · 2013 · Cancer Immunology, Immunotherapy
6. Tautomerism in drug discovery
   ALAN ROY KATRITZKY, C. Dennis Hall, Bahaa Elgendy, Bogdan Draghici · 2010 · Journal of Computer-Aided Molecular Design
7. Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
   S. Vincent Rajkumar · 2013 · American Journal of Hematology
8. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
   Rachid Baz, Thomas G. Martin, Hui‐Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn Jay Cho, Jeffrey Lee Wolf, Anuj Kumar Mahindra, Ajai Chari, Daniel M. Sullivan et al. · 2016 · Blood
9. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
   Enrique M. Ocio, David Vilanova, Peter Wisdom Atadja, Patricia Maiso, Edvan de Queiroz Crusoé, Diego Fernández‐Lázaro, Mercedes Garayoa, Laura San‐Segundo, Teresa Hernández‐Iglesias, Enrique de Álava et al. · 2009 · Haematologica
10. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Paul Gerard Guy Richardson, Sundar Jagannath, Mohamad A. Hussein, James R. Berenson, Seema Singhal, David H. Irwin, STEPHANIE F. WILLIAMS, William Bensinger, Ashraf Z. Badros, Robert Allen Vescio et al. · 2009 · Blood
11. Treatment options for relapsed and refractory multiple myeloma
    Ajay K. Nooka, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Sagar Lonial · 2015 · Blood
12. Emerging immunotherapies in multiple myeloma
    Urvi Ashok Shah, Sham Mailankody · 2020 · BMJ
13. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
    Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri, Deborah Ann Thomas, Jörge E. Cortes, Farhad Ravandi, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Carlos Bueso-Ramos, Srđan Verstovšek · 2009 · Journal of Clinical Oncology
14. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
    Paul Gerard Guy Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J. Jakubowiak, Marc Steffen Raab, Thierry T.F. Facon, Ravi Vij, Darrell J. White, Donna Ellen Reece, Lotfi Benboubker et al. · 2015 · The Lancet Haematology
15. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
    Rajkumar, S. Vincent · 2011 · American Journal of Hematology
16. Treatment of Multiple Myeloma: A Comprehensive Review
    Robert A. Kyle, S. Vincent Rajkumar · 2009 · Clinical Lymphoma & Myeloma
17. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Michael Blake Streiff, Bjorn Holmstrom, Dana Elizabeth Angelini, Aneel A. Ashrani, Amro Elshoury, John R. Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Zachary Goldhaber et al. · 2021 · PubMed
18. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    Meletios Athanasios Dimopoulos, Paul Gerard Guy Richardson, Nancy A. Brandenburg, Zhinuan Yu, Donna M. Weber, Rubén Niesvizky, Gareth John Morgan · 2012 · Blood
19. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
    Benjamin G. Barwick, Paola E. Neri, Nizar Jacques Bahlis, Ajay K. Nooka, Madhav V. Dhodapkar, David L. Jaye, Craig C. Hofmeister, Jonathan L. Kaufman, Vikas Anand Gupta, Daniel Auclair et al. · 2019 · Nature Communications
20. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
    Alexandra G. Smith, Eve Roman, Debra A. Howell, Richard Jones, Russell D. Patmore, Andrew Jack · 2009 · British Journal of Haematology
21. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    Antonio Pierangelo Palumbo, Orhan Sezer, Robert A. Kyle, Jesús F. San Miguel, Robert Zygmunt Orlowski, Philippe Moreau, Rubén Niesvizky, Gareth John Morgan, Raymond L. Comenzo, Pieter Sonneveld et al. · 2009 · Leukemia
22. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
    Rajkumar, S. Vincent · 2012 · American Journal of Hematology
23. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
    Inger S. Nijhof, Niels W.C.J. van de Donk, Sonja Zweegman, Henk M. Lokhorst · 2017 · Drugs
24. Therapy for Relapsed Multiple Myeloma
    David Dingli, Sikander Ailawadhi, Peter Leif Bergsagel, Francis K. Buadi, Angela A. Dispenzieri, Rafaël Fonseca, Morie Abraham Gertz, Wilson I. Gonsalves, Susan R. Hayman, Prashant Kapoor et al. · 2017 · Mayo Clinic Proceedings
25. Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    Jesús F. San Miguel, Paul Gerard Guy Richardson, Andreas Günther, Orhan Sezer, David Samuel DiCapua Siegel, Joan Bladé, Richard LeBlanc, Heather J. Sutherland, Monika Sopala, Kaushal Mishra et al. · 2013 · Journal of Clinical Oncology
26. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
    Pawel J. Robak, Tadeusz Robak · 2019 · Drugs in R&D
27. Multiple Myeloma
    Jacob P. Laubach, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2010 · Annual Review of Medicine
28. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
    Hervé Avet‐Loiseau, Jean Soulier, Jean‐Paul Fermand, Ibrahim Yakoub‐Agha, Michel Attal, Cyrille Hulin, Laurent Garderet, Karim Belhadj, Véronique Dorvaux, Stéphane Minvielle et al. · 2010 · Leukemia
29. Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
    Jan, Max, Sperling, Adam S., Ebert, Benjamin L. · 2021 · Nature Reviews Clinical Oncology
30. Approach to the treatment of multiple myeloma: a clash of philosophies
    S. Vincent Rajkumar, Gösta Gahrton, Peter Leif Bergsagel · 2011 · Blood
31. Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
    Siow Ming Lee, Penella J. Woll, Robin Rudd, David Raymond Ferry, Mary E.R. O'Brien, Gary Middleton, Stephen G Spiro, Lindsay E. James, Kulsam Ali, Mark Jitlal et al. · 2009 · JNCI Journal of the National Cancer Institute
32. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
    Hervé Avet‐Loiseau, Heinz Ludwig, Ola Landgren, Bruno Paiva, Chris Morris, Hui Yang, Kefei Zhou, Sunhee Kwon Ro, María‐Victoria Mateos · 2019 · Clinical Lymphoma Myeloma & Leukemia
33. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
    Meletios Athanasios Dimopoulos, Adrián Macías Alegre, Edward Allen Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Ellen Reece, Marta Olesnyckyj, Zhinuan Yu et al. · 2010 · Cancer
34. Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
    Fink, Emma C., McConkey, Marie, Adams, Dylan N., Haldar, Saurav D., Kennedy, James A., Guirguis, Andrew A., Udeshi, Namrata D., Mani, D. R., Chen, Michelle, Liddicoat, Brian et al. · 2018 · Blood
35. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
    Bjorklund, C C, Baladandayuthapani, V, Lin, H Y, Jones, R J, Kuiatse, I, Wang, H, Yang, J, Shah, J J, Thomas, S K, Wang, M et al. · 2014 · Leukemia
36. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Annemiek Broyl, Rowan Kuiper, Mark van Duin, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Sonja Zweegman, Arjan Buijs, Dirk Hose, Henk M. Lokhorst et al. · 2012 · Blood
37. Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
    Bjorklund, Chad C., Ma, Wencai, Wang, Zhi-Qiang, Davis, R. Eric, Kuhn, Deborah J., Kornblau, Steven M., Wang, Michael, Shah, Jatin J., Orlowski, Robert Z. · 2011 · Journal of Biological Chemistry
38. The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
    Kenneth Carl Anderson · 2012 · Journal of Clinical Oncology
39. Continued survival gains in recent years among critically ill myeloma patients
    Vincent Peigne, Kateřina Rusínová, Lionel Karlin, Michaël Darmon, Jean‐Paul Fermand, Benoı̂t Schlemmer, Élie Azoulay · 2008 · Intensive Care Medicine
40. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
    Michael L. Wang, Tom G. Martin, William Bensinger, Melissa Alsina, David Samuel DiCapua Siegel, Edward Kavalerchik, Mei Huang, Robert Zygmunt Orlowski, Rubén Niesvizky · 2013 · Blood
41. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
    Karin Jordan, Irina Proskorovsky, Philip Lewis, Jack Ishak, Krista A. Payne, Noreen D. Lordan, Charalampia A. Kyriakou, C. D. Williams, Sarah Peters, Faith E. Davies · 2013 · Supportive Care in Cancer
42. Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐ CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma
    Jonathan L. Kaufman, Rubén Niesvizky, Edward Allen Stadtmauer, Asher Alban Chanan-Khan, David Samuel DiCapua Siegel, Heather Bethea Horne, William A. Wegener, David M. Goldenberg · 2013 · British Journal of Haematology
43. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay, Suzanne R. Hayman, Martha Q. Lacy, Francis K. Buadi, Morie Abraham Gertz, Shaji Kunnathu Kumar, Angela A. Dispenzieri, Joseph R Mikhael, Peter Leif Bergsagel, David Dingli et al. · 2009 · Blood
44. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
    Chrissy H.Y. van Beurden-Tan, Margreet G. Franken, Hedwig M. Blommestein, Carin A. Uyl‐de Groot, Pieter Sonneveld · 2017 · Journal of Clinical Oncology
45. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
    Meletios Athanasios Dimopoulos, Xavier P Leleu, Antonio Pierangelo Palumbo, Philippe Moreau, Michel Delforge, Michèle Cavo, Heinz Ludwig, Gareth John Morgan, Faith E. Davies, Pieter Sonneveld et al. · 2014 · Leukemia
46. An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
    Sundar Jagannath, Ravi Vij, A. Keith Stewart, Suzanne Trudel, Andrzej J. Jakubowiak, Tony Reiman, George Somlo, Nizar Jacques Bahlis, Sagar Lonial, Lori Kunkel et al. · 2012 · Clinical Lymphoma Myeloma & Leukemia
47. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
    Pier Luigi Zinzani, Julie Marie Vose, M. S. Czuczman, Craig B. Reeder, Corinne Haïoun, Jonathan A. Polikoff, Hervé Tilly, Lillian F. Zhang, K. Prandi, J. Li et al. · 2013 · Annals of Oncology
48. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
    Hermann Brenner, Ádám Gondos, Dianne D. Pulte · 2009 · Haematologica
49. Lenalidomide mode of action: linking bench and clinical findings
    Faith E. Davies, Rachid Baz · 2010 · Blood Reviews
50. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
    Stefan Tobias Knop, Christian Gerecke, Peter Liebisch, Max S. Topp, Uwe Platzbecker, Orhan Sezer, Christina Vollmuth, Karina Falk, Axel Glasmacher, Uwe Maeder et al. · 2009 · Blood
51. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
    Suzanne Lentzsch, Amy O'Sullivan, Ryan C. Kennedy, Mohammad Abbas, Lijun Dai, Silvana Lalo Pregja, Steve Burt, Michael M. Boyiadzis, G. David Roodman, Markus Y. Mapara et al. · 2012 · Blood
52. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    Meletios Athanasios Dimopoulos, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Aslani Gkotzamanidou, Marina Iakovaki, C. Matsouka, Despoina Mparmparoussi, Μαρία Ρούσσου et al. · 2010 · Leukemia
53. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
    Meletios Athanasios Dimopoulos, Antonio Pierangelo Palumbo, Michel Attal, Meral Beksaç, Faith E. Davies, Michel Delforge, Hermann Einsele, Roman Hájek, Jean‐Luc Harousseau, F Leal da Costa et al. · 2011 · Leukemia
54. Thrombosis in Multiple Myeloma
    Sigurdur Yngvi Kristinsson · 2010 · Hematology
55. Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma
    Tomer Martin Mark, Jessica L. Stern, Jessica R. Furst, David S. Jayabalan, Faiza Zafar, April LaRow, Roger Niles Pearse, John G. Harpel, Tsiporah B. Shore, Michael W. Schuster et al. · 2008 · Transplantation and Cellular Therapy
56. Kidney dysfunction during lenalidomide treatment for AL amyloidosis
    R. Specter, Vaishali Sanchorawala, David C. Seldin, Anthony C Shelton, Salli A Fennessey, Kyle T. Finn, Jerome B. Zeldis, Laura M. Dember · 2010 · Nephrology Dialysis Transplantation
57. Resistance to proteasome inhibitors and other targeted therapies in myeloma
    Craig Thomas Wallington-Beddoe, Magdalena Sobieraj‐Teague, Bryone Jean Kuss, Stuart Maxwell Pitson · 2018 · British Journal of Haematology
58. Multiple myeloma: practice patterns across Europe
    Marc Steffen Raab, Michèle Cavo, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez‐McQuire, Reza Safaei, Lionel Karlin, María‐Victoria Mateos et al. · 2016 · British Journal of Haematology
59. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
    Jean‐Luc Harousseau, Meletios Athanasios Dimopoulos, M. Wang, Alessandro Corso, Christine Lynn Chen, Michel Attal, A. Spencer, Zhinuan Yu, Marta Olesnyckyj, J. B. Zeldis et al. · 2010 · Haematologica
60. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
    Charles Eby · 2009 · British Journal of Haematology
61. Review of health-related quality of life data in multiple myeloma patients treated with novel agents
    Pieter Sonneveld, Silvia G. R. Verelst, P Lewis, Vanessa C. Gray‐Schopfer, Andrew Hutchings, Annabel Nixon, Maria Teresa Petrucci · 2013 · Leukemia
62. A phase-2 trial of low-dose pomalidomide in myelofibrosis
    Kebede H. Begna, Ruben A. Mesa, Animesh Dev Pardanani, William J. Hogan, Mark Robert Litzow, Rebecca F. McClure, Ayalew Tefferi · 2010 · Leukemia
63. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Torben Plesner, Hendrik‐Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Pierangelo Palumbo, Steen Lisby et al. · 2016 · Blood
64. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia
    Michael Auerbach, Jennifer A. Pappadakis, Huzefa Bahrain, Sarah A Auerbach, Harold S. Ballard, Naomi V. Dahl · 2011 · American Journal of Hematology
65. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
    Edward Allen Stadtmauer, Donna M. Weber, Rubén Niesvizky, Andrew Belch, Miles H. Prince, Jesús F. San Miguel, Thierry T.F. Facon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis et al. · 2009 · European Journal Of Haematology
66. Management of cardiovascular risk in patients with multiple myeloma
    Chris Plummer, Christoph Driessen, Zsolt Roland Szabó, María‐Victoria Mateos · 2019 · Blood Cancer Journal
67. The role of P-glycoprotein in drug resistance in multiple myeloma
    Joseph Abraham, Noha Nabil Salama, Abdel Kareem Azab · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
68. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
    Michael V. Lioznov, Jean El Cheikh, Franz Albert Hoffmann, York Hildebrandt, Francis Ayuketang Ayuk, Christine Wolschke, Djordje Atanackovic, Georgia Schilling, Anita Badbaran, Ulrike Bacher et al. · 2009 · Bone Marrow Transplantation
69. Cancer Interception
    Elizabeth Helen Blackburn · 2011 · Cancer Prevention Research
70. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
    Robert Frank Cornell, Adetola A. Kassim · 2016 · Bone Marrow Transplantation
71. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies
    Weijuan Li, David A. Garcia, Robert Frank Cornell, David Gailani, Jacob P. Laubach, Michelle E. Maglio, Paul Gerard Guy Richardson, Javid J. Moslehi · 2016 · JAMA Oncology
72. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
    Benedetto Bruno, Marcello Rotta, Francesca F. Patriarca, Daniele Giovanni Mattei, Bernardino Allione, Fabrizio Carnevale‐Schianca, Roberto Sorasio, Alessandro Rambaldi, Marco Casini, Matteo Parma et al. · 2008 · Blood
73. Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma
    Greg Dueck, Neil Sun Chua, Angeli Prasad, Daygen L. Finch, Doug Stewart, Darrell J. White, Richard van der Jagt, James B. Johnston, Andrew R. Belch, Tony Reiman · 2010 · Cancer
74. Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Kyriakos P. Papadopoulos, David Samuel DiCapua Siegel, David H. Vesole, Peter Lee, Steven T. Rosen, Naseem J. Zojwalla, Joseph R. Holahan, Susan Lee, Zhengping Wang, Ashraf Z. Badros · 2014 · Journal of Clinical Oncology
75. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome
    Satoshi Kuwabara, Sonoko Misawa, Kazuaki Kanai, Setsu Sawai, Takamichi Hattori, M Nishimura, Chiaki Nakaseko · 2008 · Journal of Neurology Neurosurgery & Psychiatry
76. NF-??B in the pathogenesis and treatment of multiple myeloma
    Zhiwei Li, Haiming Chen, Richard A. Campbell, Benjamin Bonavida, James R. Berenson · 2008 · Current Opinion in Hematology
77. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM
    Shirong Li, Rekha Pal, Sara A. Monaghan, Peter H Schafer, Hongjiao Ouyang, Markus Y. Mapara, Deborah Lynn Galson, Suzanne Lentzsch · 2011 · Blood
78. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
    Axel Schulenburg, Katharina Blatt, Sabine Cerny‐Reiterer, Irina Sadovnik, Harald Herrmann, Brigitte Marian, Thomas W. Grunt, Christoph Carl Zielinski, Peter Valent · 2015 · Journal of Hematology & Oncology
79. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
    Sagar Lonial, Paul Gerard Guy Richardson, Jesús F. San Miguel, Pieter Sonneveld, Michael W. Schuster, Joan Bladé, Jamie D. Cavenagh, S. Vincent Rajkumar, Andrzej J. Jakubowiak, Dixie-Lee W. Esseltine et al. · 2008 · British Journal of Haematology
80. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century
    Dianne D. Pulte, Lina Jansen, Felipe Andres Castro, Katharina Emrich, Alexander Katalinic, Bernd Holleczek, Hermann Brenner, the GEKID Cancer Survival Working Group · 2015 · British Journal of Haematology
81. Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Martha Q. Lacy, Sumithra J. Mandrekar, Angela A. Dispenzieri, Suzanne R. Hayman, Shaji Kunnathu Kumar, Francis K. Buadi, David Dingli, Mark Robert Litzow, Peter J. Wettstein, Douglas J. Padley et al. · 2009 · American Journal of Hematology
82. Turning liabilities into opportunities: Off-target based drug repurposing in cancer
    Vinayak C. Palve, Yi Liao, Lily L. Remsing Rix, Uwe Rix · 2020 · Seminars in Cancer Biology
83. Pomalidomide
    Martha Q. Lacy, Arleigh B. Robertson McCurdy · 2013 · Blood
84. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
    Thomas Elmer Witzig, Grzegorz S. Nowakowski, Thomas Matthew Habermann, Andre Henri Goy, Francisco J. Hernandez‐Ilizaliturri, Annalisa Chiappella, Umberto Vitolo, Nathan Hale Fowler, M. S. Czuczman · 2015 · Annals of Oncology
85. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
    Heinz Ludwig, Meral Beksaç, Joan Bladé, Mario Boccadoro, Jamie D. Cavenagh, Michèle Cavo, Meletios Athanasios Dimopoulos, Johannes W. Drach, Hermann Einsele, Thierry T.F. Facon et al. · 2010 · The Oncologist
86. Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
    Christine Wolschke, Thomas Stübig, Ute Hegenbart, Stefan Olaf Schönland, Marion Heinzelmann, York Hildebrandt, Francis Ayuketang Ayuk, Djordje Atanackovic, Peter Dreger, Axel Rolf Zander et al. · 2012 · Experimental Hematology
87. Multiple myeloma
    Meletios Athanasios Dimopoulos, Evangelos Terpos · 2010 · Annals of Oncology
88. Angiogenesis: A Target in Solid Tumors, Also in Leukemia?
    Thomas Schmidt, Peter Carmeliet · 2011 · Hematology
89. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
    Enrique M. Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San‐Segundo, David Vilanova, Lucía López‐Corral, Juan Carlos Montero, Teresa Hernández‐Iglesias et al. · 2008 · Blood
90. Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death
    Peter Michael Voorhees, Qing Chen, George W. Small, Deborah J. Kuhn, Sally A. Hunsucker, Jeffrey A. Nemeth, Robert Zygmunt Orlowski · 2009 · British Journal of Haematology
91. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
    Michel Delforge, Leonard A. Minuk, J.-C. Eisenmann, Bertrand Arnulf, Letizia Canepa, Alberto Fragasso, Serge Leyvraz, Christian Langer, Yousef Ezaydi, Dan T. Vogl et al. · 2015 · Haematologica
92. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
    Rekha Pal, Sara A. Monaghan, Andrea Cortese Hassett, Markus Y. Mapara, Peter H Schafer, G. David Roodman, Margaret V. Ragni, Lynn C. Moscinski, Alan F. List, Suzanne Lentzsch · 2009 · Blood
93. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
    Enrique M. Ocio, Diego Fernández‐Lázaro, Laura San‐Segundo, Lucía López‐Corral, Luis Antonio Corchete, Norma Carmen Gutierrez, Mercedes Garayoa, Teresa Paíno, Antonio García-Gómez, M Delgado et al. · 2014 · Leukemia
94. Treatment for High-Risk Smoldering Myeloma
    Sigurdur Yngvi Kristinsson, Erik Holmberg, Cecilie Hveding Blimark · 2013 · New England Journal of Medicine
95. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
    Anupama Narla, Shilpee Dutt, J. Randall McAuley, Fátima Al‐Shahrour, Slater N. Hurst, Marie Ellen McConkey, Donna S Neuberg, Benjamin L. Ebert · 2011 · Blood
96. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
    Ola Landgren · 2013 · Hematology
97. A Diels–Alder modulated approach to control and sustain the release of dexamethasone and induce osteogenic differentiation of human mesenchymal stem cells
    Kenneth Christopher Koehler, Daniel L. Alge, Kristi S. Anseth, Christopher N. Bowman · 2013 · Biomaterials
98. Lenalidomide in the treatment of multiple myeloma: a review
    Xavier Armoiry, G. Aulagner, Thierry T.F. Facon · 2008 · Journal of Clinical Pharmacy and Therapeutics
99. Clinical pharmacokinetics and pharmacodynamics of lenalidomide
    Chen, Nianhang, Zhou, Simon, Palmisano, Maria · 2017 · Clinical Pharmacokinetics
100. Management of older adults with multiple myeloma
     Antonio Pierangelo Palumbo, Roberto Mina · 2013 · Blood Reviews